Endoscopic findings of immune checkpoint inhibitor-related gastrointestinal adverse events
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The use of immune checkpoint inhibitors (ICIs) for the treatment of various malignancies is increasing. Immune-related adverse events can occur after ICI administration, with gastrointestinal adverse events constituting a significant proportion of these events. When ICI-related diarrhea/colitis is suspected, endoscopic evaluation is recommended to differentiate it from other etiologies and assess the severity of colitis. The distribution of intestinal inflammation in ICI-related colitis demonstrates a high frequency of extensive colitis (23–86%). However, isolated right-sided colitis (3–8%) and ileitis (2–16%) are less prevalent. Endoscopic findings vary and predominantly encompass features indicative of inflammatory bowel disease, including aphthae, ulcers, diffuse or patchy erythema, mucosal edema, loss of vascular pattern, and friability. The presence of ulcers and extensive intestinal inflammation are associated with a reduced response to treatment. Microscopic inflammation can be observed even in endoscopically normal mucosa, underscoring the need for biopsies of seemingly normal mucosa. Histological findings present with acute/chronic inflammation and occasionally exhibit characteristics observed in inflammatory bowel disease, microscopic colitis, or ischemic colitis. The first-line therapeutic choice for ICI-related diarrhea/colitis with a common terminology criteria for adverse events grade of 2 or above is corticosteroids, whereas infliximab and vedolizumab are recommended for refractory cases.
Abstract
The use of immune checkpoint inhibitors (ICIs) for the treatment of various malignancies is increasing. Immune-related adverse events can occur after ICI administration, with gastrointestinal adverse events constituting a significant proportion of these events. When ICI-related diarrhea/colitis is suspected, endoscopic evaluation is recommended to differentiate it from other etiologies and assess the severity of colitis. The distribution of intestinal inflammation in ICI-related colitis demonstrates a high frequency of extensive colitis (23–86%). However, isolated right-sided colitis (3–8%) and ileitis (2–16%) are less prevalent. Endoscopic findings vary and predominantly encompass features indicative of inflammatory bowel disease, including aphthae, ulcers, diffuse or patchy erythema, mucosal edema, loss of vascular pattern, and friability. The presence of ulcers and extensive intestinal inflammation are associated with a reduced response to treatment. Microscopic inflammation can be observed even in endoscopically normal mucosa, underscoring the need for biopsies of seemingly normal mucosa. Histological findings present with acute/chronic inflammation and occasionally exhibit characteristics observed in inflammatory bowel disease, microscopic colitis, or ischemic colitis. The first-line therapeutic choice for ICI-related diarrhea/colitis with a common terminology criteria for adverse events grade of 2 or above is corticosteroids, whereas infliximab and vedolizumab are recommended for refractory cases.
참고문헌 (42)
- Hodi FS, "Improved survival with ipilimumab in patients with metastatic melanoma", N Engl J Med, 363, pp.711~723 (2010)
- Robert C, "A decade of immune-checkpoint inhibitors in cancer therapy", Nat Commun, 11, pp.3801~ (2020)
- Jain KK, "Personalized immuno-oncology", Med Princ Pract, 30, pp.1~16 (2021)
- Seidel JA, "Anti-PD-1 and anti-CTLA-4therapies in cancer : mechanisms of action, efficacy, and limitations", Front Oncol, 8, pp.86~ (2018)
- Postow MA, "Immune-related adverse events associated with immune checkpoint blockade", N Engl J Med, 378, pp.158~168 (2018)
- Hwang SW, "Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis : a review", Intest Res, 21, pp.433~442 (2023)
- Gong Z, "Immune checkpoint inhibitor-mediated diarrhea and colitis : a clinical review", JCO Oncol Pract, 16, pp.453~461 (2020)
- Weber JS, "Management of immune-related adverse events and kinetics of response with ipilimumab", J Clin Oncol, 30, pp.2691~2697 (2012)
- Robert C, "Pembrolizumab versus ipilim umab in advanced melanoma", N Engl J Med, 372, pp.2521~2532 (2015)
- Wang DY, "Clinical characterization of colitis arising from anti-PD-1 based therapy", Oncoimmunology, 8, pp.e1524695~ (2019)
- "Common Termi nology Criteria for Adverse Events (CTCAE) version 5.0" (2017)[URL]
- Abu-Sbeih H, "Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis", J Immunother Cancer, 6, pp.95~ (2018)
- De Silva S, "Flexible sigmoidoscopy may be sufficient for initial evaluation of suspected immunotherapy-me diated colitis : a cross-sectional study", J Gastroenterol Hepatol, 37, pp.284~290 (2022)
- Kou F, "Immune checkpoint inhibitor-induced colitis with endoscopic evaluation in Chinese cancer patients : a single-cen tre retrospective study", Front Oncol, 13, pp.1285478~ (2023)
- Wang Y, "Endoscopic and histologic fea tures of immune checkpoint inhibitor-related colitis", Inflamm Bowel Dis, 24, pp.1695~1705 (2018)
- Dougan M, "AGA clinical practice up date on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis : expert review", Gastroenterology, 160, pp.13841393~ (2021)
- Powell N, "British Society of Gastroenter ology endorsed guidance for the management of immune check point inhibitor-induced enterocolitis", Lancet Gastroenterol Hepatol, 5, pp.679~697 (2020)
- Thompson JA, "NCCN guidelines insights : management of immunotherapy-related toxicities, version 1. 2020", J Natl Compr Canc Netw, 18, pp.230~241 (2020)
- Hata J, "The use of transabdominal ultrasound in in flammatory bowel disease", Korean J Radiol, 23, pp.308~321 (2022)
- Takenaka K, "Artificial intelli gence for endoscopy in inflammatory bowel disease", Intest Res, 20, pp.165~170 (2022)
- Sakurai K, "Characteristics and use fulness of transabdominal ultrasonography in immune-mediated colitis", Intest Res, 21, pp.126~136 (2023)
- Coutzac C, "Colon immune-related adverse events : anti-CTLA-4 and anti-PD-1 blockade induce distinct immu nopathological entities", J Crohns Colitis, 11, pp.1238~1246 (2017)
- Geukes Foppen MH, "Immune check point inhibition-related colitis : symptoms, endoscopic features, histol ogy and response to management", ESMO Open, 3, pp.e000278~ (2018)
- Marthey L, "Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bow el disease", J Crohns Colitis, 10, pp.395~401 (2016)
- Yamauchi R, "The characteristics of nivolumab-induced colitis : an evaluation of three cases and a litera ture review", BMC Gastroenterol, 18, pp.135~ (2018)
- Yanai S, "Immune checkpoint inhib itor-induced diarrhea : clinicopathological study of 11 patients", Dig Endosc, 32, pp.616~620 (2020)
- Wright AP, "Systematic review and case series : flexible sigmoidoscopy identifies most cases of checkpoint inhibitor-induced colitis", Aliment Pharmacol Ther, 49, pp.14741483~ (2019)
- Gonzalez RS, "PD-1 inhibitor gas troenterocolitis : case series and appraisal of 'immunomodulatory gastroenterocolitis'", Histopathology, 70, pp.558~567 (2017)
- Kubo K, "Nivolumab-associated colitis mimicking ulcerative colitis", Clin Gastroenterol Hepatol, 15, pp.A35~A36 (2017)
- Parente P, "Clinic, endoscopic and histological features in patients treated with ICI developing GI tox icity : some news and reappraisal from a mono-institutional experi ence", Diagnostics(Basel), 12, pp.685~ (2022)
- Verschuren EC, "Clinical, endoscopic, and histologic characteristics of ipilimumab-associated colitis", Clin Gastroenterol Hepatol, 14, pp.836~842 (2016)
- Nishida T, "Immune checkpoint inhibitor-in duced diarrhea", colitis : endoscopic and pathologic findings, 2019, pp.10, 17~28
- Bonanno L, "Immune-related diarrhea and colitis in non-small cell lung cancers : impact of multidisciplinary management in a real-world setting", Oncologist, 29, pp.e118~e130 (2024)
- Cheung VT, "Immune checkpoint inhibitor-related colitis assessment and prognosis : can IBD scoring point the way?", Br J Cancer, 123, pp.207~215 (2020)
- Hughes MS, "Budesonide treatment for microscopic colitis from immune checkpoint inhibitors", J Immuno ther Cancer, 7, pp.292~ (2019)
- Ibraheim H, "Topical beclometasone dipropi onate in the management of immune checkpoint inhibitor-induced microscopic colitis", BMJ Case Rep, 12, pp.e226481~ (2019)
- Alexander JL, "Oral beclomethasone dipropionate is an effective treatment for immune checkpoint inhib itor induced colitis", J Immunother Cancer, 10, pp.e005490~ (2022)
- Abu-Sbeih H, "Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced coli tis : a multi-center study", J Immunother Cancer, 6, pp.142~ (2018)
- Johnson DH, "Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis", J Immunother Cancer, 6, pp.103~ (2018)
- Zou F, "Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer : a two-center observational study", J Immuno ther Cancer, 9, pp.e003277~ (2021)
- Boivineau G, "Biologic therapy for budesonide-refractory, -dependent or-intolerant microscopic coli tis : a multicentre cohort study from the GETAID", J Crohns Colitis, 16, pp.1816~1824 (2022)
- Druez A, "JAK inhibitor, a new player for treat ment-refractory microscopic colitis", Intest Res, 21, pp.411~412 (2023)